Bagsværd, Denmark, 22 April 2015 - At Novo Nordisk's Annual General Meeting on 19 March 2015, it was decided to reduce the company's B share capital from DKK 422,512,800 to DKK 412,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Further information
Media: | ||
Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com: mailto:krop@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com: mailto:dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com: mailto:mrz@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com: mailto:fdni@novonordisk.com |
Company announcement No 27 / 2015
http://hugin.info/2013/R/1913419/683321.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire